Q-omics provides the consensus-scored SEC61GP1 profile across patient tissues and cancer cell-line models. SEC61GP1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SEC61GP1 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, SEC61GP1 RNA expression shows 5,781 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KIRC, and STAD as cancer lineages where SEC61GP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC61GP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC61GP1 survival associations across molecular data types. SEC61GP1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC61GP1 RNA expression–survival associations across cancer types. High SEC61GP1 expression shows unfavorable associations in UVM, KIRC, THYM, UCEC, CESC and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for SEC61GP1 RNA expression.
This table summarizes SEC61GP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SEC61GP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC61GP1 shows higher tumor expression in KIRC. The KIRC box plot shows higher SEC61GP1 RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p = .023).
This table shows molecular features associated with SEC61GP1 in patient tissues and cancer cell lines. In patient samples, SEC61GP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
